erpreted as demonstrating that the medicine has a negative side effect on some a condition of the grant, the professor was required to submit a preliminary draft of the pharmaceutical company, for review and feedback. The professor submitted the quired, and the pharmaceutical company wrote back to ask whether the professor der deleting the ambiguous data, as it may reflect badly on the pharmaceutical d it is not strong data to begin with. The professor has reached the end of the grant d to continue the research would need to get additional funding, with one obvious nding being the pharmaceutical company